title: Change in amniotic fluid levels of multiple anti-angiogenic proteins before development of preeclampsia and intrauterine growth restriction.
abstract: BACKGROUND
  The cause of preeclampsia remains unknown. Excessive antiangiogenic proteins have been proposed to play a pathogenic role in preeclampsia.
  
  
  OBJECTIVE
  Our objective was to determine the differences in soluble endoglin (sEndoglin), soluble fms-like tyrosine kinase receptor-1 (sFLT1), leptin, adiponectin, and endothelin 1 concentrations between normal and preeclampsia amniotic fluid (AF). Such results may help us understand the pathophysiology of preeclampsia.
  
  
  METHODS
  We performed a nested case-control study. Seventy-one women with preeclampsia were matched to 71 normotensive controls. The preeclamptic women were broken into two subgroups according to the association with fetal intrauterine growth restriction (IUGR). AF concentrations of sEndoglin, sFLT1, leptin, adiponectin, and endothelin 1 were measured by ELISA. Receiver-operating characteristics curve analysis was used to compare the discriminative values of these potential biomarkers. Functional network analysis was performed using MetaCore to reveal the common functions of the interacting proteins.
  
  
  RESULTS
  Increased AF concentrations of sFLT1, sEndoglin, endothelin 1, and leptin were found in women who later developed preeclampsia. sFLT1, sEndoglin, leptin, and adiponectin were significantly higher in the preeclampsia with IUGR than those without IUGR. Leptin has the largest area under the curve (0.753). Network analysis revealed that elevated amniotic proteins are involved in the inflammatory process of the human placenta.
  
  
  CONCLUSIONS
  Significant elevation of leptin can be detected in AF 2 months earlier than the appearance of symptoms; thus, it may be used as a predictive marker for preeclampsia. The increase of these antiangiogenic proteins supports the roles of inflammation and oxidative stress in pathogenesis of preeclampsia.
authors.affiliation: No.5, Fu-Shin Road, Gwei-Shan, Tao-Yuan 333, Taiwan.
authors.forename: Chao-Nin
authors.initials: CN
authors.lastname: Wang
authors.forename: Shuenn-Dyh
authors.initials: SD
authors.lastname: Chang
authors.forename: Hsiu-Huei
authors.initials: HH
authors.lastname: Peng
authors.forename: Yun-Shien
authors.initials: YS
authors.lastname: Lee
authors.forename: Yao-Lung
authors.initials: YL
authors.lastname: Chang
authors.forename: Po-Jen
authors.initials: PJ
authors.lastname: Cheng
authors.forename: An-Shine
authors.initials: AS
authors.lastname: Chao
authors.forename: Tzu-Hao
authors.initials: TH
authors.lastname: Wang
authors.forename: Hsin-Shih
authors.initials: HS
authors.lastname: Wang
mesh_terms: D052242:Adiponectin / Q000032:analysis; D000328:Adult; D000653:Amniotic Fluid / Q000737:chemistry*; D000704:Analysis of Variance; D015703:Antigens, CD / Q000032:analysis; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D000071063:Endoglin; D019332:Endothelin-1 / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005317:Fetal Growth Retardation / Q000378:metabolism*; D006801:Humans; D020738:Leptin / Q000032:analysis; D011225:Pre-Eclampsia / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism; D011237:Predictive Value of Tests; D011247:Pregnancy; D011446:Prospective Studies; D012372:ROC Curve; D011956:Receptors, Cell Surface / Q000032:analysis; D012044:Regression Analysis; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000032:analysis
chemical_list: D052242:Adiponectin; D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D019332:Endothelin-1; D020738:Leptin; D011956:Receptors, Cell Surface; D040281:Vascular Endothelial Growth Factor Receptor-1